Lamivudine bound in HBV polymerase


SeqHepB is a predictive tool for clinicians in the comprehensive management of the HBV disease, assisting the clinician to make an informed decision as to drug selection based on the mutational and resistance profile of the virus in an individual patient at any given time.

Specifically it:

  • Increases efficacious use of existing and new therapeutics for treating and managing CH-B
  • Improves the likelihood of clinician's ability to monitor and individualize the patient's drug regimes
  • Arms the treating clinician with an additional decision support tool to manage cross-resistance and multi-drug resistance
  • Provides new information as it is captured through its dynamic and continually growing data-base